QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
The QuantifyHER study, sponsored by the Abramson Cancer Center at Penn Medicine, aims to evaluate a quantitative HER2 assay for its ability to predict treatment response in patients with HER2-low metastatic breast cancer receiving T-DXd (Enhertu). This study targets a niche yet significant segment of the breast cancer market, particularly focusing on patients with HER2 IHC 1+ expression. The findings could enhance the precision of HER2-targeted therapies, potentially leading to improved patient outcomes and positioning the sponsor favorably in the competitive landscape of breast cancer therapeutics. The study's collaboration with Danaher Inc. may also indicate a strategic partnership for diagnostic development, which could further strengthen market positioning.
Indication: HER2-positive Metastatic Breast Cancer
Modality: RNA therapy
Target: HER2 (Human Epidermal Growth Factor Receptor 2)
Sponsor: Abramson Cancer Center at Penn Medicine
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 21, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: HER2 (Human Epidermal Growth Factor Receptor 2)
View original source fields
Condition raw: HER2-positive Metastatic Breast Cancer
Condition normalized: HER2-positive Metastatic Breast Cancer
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: HER2 (Human Epidermal Growth Factor Receptor 2)
Target normalized: HER2 (Human Epidermal Growth Factor Receptor 2)